Clinical management of metastatic colorectal cancer in the era of precision medicine
暂无分享,去创建一个
[1] F. Ciardiello,et al. Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data , 2022, Journal of personalized medicine.
[2] M. Ebert,et al. Precision medicine for metastatic colorectal cancer in clinical practice , 2022, Therapeutic advances in medical oncology.
[3] F. Ciardiello,et al. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. , 2022, Clinical colorectal cancer.
[4] D. Hanahan. Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.
[5] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[6] Vijay Kumar Chattu,et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 , 2021, JAMA oncology.
[7] Myung Ah Lee,et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. , 2021, The Lancet. Oncology.
[8] J. Tabernero,et al. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer , 2021, Current Treatment Options in Oncology.
[9] A. Carrato,et al. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[10] N. Normanno,et al. Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy , 2021, Cancers.
[11] E. Van Cutsem,et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Adagrasib Data Create Buzz at ESMO. , 2021, Cancer discovery.
[13] V. Heinemann,et al. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] F. Kiessling,et al. Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth , 2021, Journal of experimental & clinical cancer research : CR.
[15] G. Fontanini,et al. LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO , 2021, Annals of Oncology.
[16] J. Christensen,et al. LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation , 2021, Annals of Oncology.
[17] L. Antonuzzo,et al. 383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC) , 2021, Annals of Oncology.
[18] N. Normanno,et al. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. , 2021, JAMA oncology.
[19] G. Martini,et al. Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? , 2021, Cancer treatment and research communications.
[20] R. Lothe,et al. Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer , 2021, NPJ genomic medicine.
[21] D. Aust,et al. Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer , 2021, Clinical Cancer Research.
[22] Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. , 2021, Clinical colorectal cancer.
[23] M. Fassan,et al. The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies☆ , 2021, ESMO open.
[24] A. Patnaik,et al. A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. , 2021 .
[25] N. Sharma,et al. Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC). , 2021 .
[26] J. Desai,et al. BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC). , 2021 .
[27] A. Grothey,et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. , 2021, The Lancet. Oncology.
[28] R. Bernards,et al. Precision oncology in metastatic colorectal cancer — from biology to medicine , 2021, Nature Reviews Clinical Oncology.
[29] C. Bokemeyer,et al. BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database. , 2021, Journal of the National Cancer Institute.
[30] K. Bencardino,et al. Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA , 2021, Targeted Oncology.
[31] Yu-qin Mao,et al. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer , 2021, Theranostics.
[32] D. Schrag,et al. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. , 2021, JAMA.
[33] T. Mohr,et al. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype , 2021, Medical Oncology.
[34] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[35] J. Desai,et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] I. Soubeyran,et al. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial , 2021, Clinical Cancer Research.
[37] Xiaohong Yan,et al. Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study , 2020, Frontiers in Oncology.
[38] I. Gupta,et al. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements , 2020, International journal of molecular sciences.
[39] L. Diaz,et al. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. Gibbs,et al. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. , 2020, The New England journal of medicine.
[41] D. Tu,et al. Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial , 2020, Clinical Cancer Research.
[42] G. Maddern,et al. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry , 2020, Targeted Oncology.
[43] Y. Bang,et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.
[44] V. Torri,et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial , 2020, ESMO Open.
[45] F. Powrie,et al. Host–microbiota maladaptation in colorectal cancer , 2020, Nature.
[46] F. Ciardiello,et al. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer , 2020, ESMO Open.
[47] Masato Nakamura,et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08 , 2020, British Journal of Cancer.
[48] F. Ciardiello,et al. How we treat metastatic colorectal cancer , 2020, ESMO open.
[49] Mark Robson,et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] Masato Nakamura,et al. RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer , 2020 .
[51] V. Silva,et al. Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis , 2020, Ecancermedicalscience.
[52] J. Tabernero,et al. Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer , 2020, Therapeutic advances in medical oncology.
[53] J. Medema,et al. Exploring and modelling colon cancer inter-tumour heterogeneity: opportunities and challenges , 2020, Oncogenesis.
[54] J. Tabernero,et al. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer , 2020 .
[55] M. Fassan,et al. KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. , 2020, Clinical colorectal cancer.
[56] D. Tu,et al. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer , 2020, JAMA oncology.
[57] S. Nomura,et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] F. Ciardiello,et al. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? , 2020, Cancer treatment reviews.
[59] D. Rossini,et al. Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. , 2020, Clinical colorectal cancer.
[60] A. Jemal,et al. Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[61] Vinod Sharma,et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. , 2020, The New England journal of medicine.
[62] Ekrem Çakar,et al. The Prognostic Value of 18F-FDG PET/CT and KRAS Mutation in Colorectal Cancers , 2020, Molecular imaging and radionuclide therapy.
[63] M. Fassan,et al. The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer , 2020, Cancer Cell International.
[64] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[65] Weiqi Wang,et al. Characterizing MRI features of rectal cancers with different KRAS status , 2019, BMC Cancer.
[66] W. Scheithauer,et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[67] V. Heinemann,et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] N. Kemeny,et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial , 2019, Annals of Oncology.
[69] Yusuke Nakamura,et al. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study , 2019, Annals of Oncology.
[70] S. Shiraishi,et al. CT texture analysis for the prediction of KRAS mutation status in colorectal cancer via a machine learning approach. , 2019, European journal of radiology.
[71] V. Adamo,et al. Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.
[72] Raja R. Narayan,et al. Role of Hepatic Artery Infusion Chemotherapy in Treatment of Initially Unresectable Colorectal Liver Metastases: A Review. , 2019, JAMA surgery.
[73] S. Kopetz,et al. Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A Review of Current Knowledge with a Focus on Rechallenge Therapies , 2019, Clinical Cancer Research.
[74] F. Ciardiello,et al. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. , 2019, Cancer treatment reviews.
[75] Jun Yu,et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis , 2019, Gut.
[76] V. Heinemann,et al. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. , 2019, The Lancet. Oncology.
[77] M. Bertagnolli,et al. Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] G. Bregni,et al. HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer. , 2019, JAMA oncology.
[79] L. Crinò,et al. Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence , 2019, OncoTargets and therapy.
[80] V. Torri,et al. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. , 2019, The oncologist.
[81] R. Deng,et al. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma , 2019, Clinical Cancer Research.
[82] J. Hainsworth,et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. , 2019, The Lancet. Oncology.
[83] N. Normanno,et al. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer , 2019, Molecular Cancer Therapeutics.
[84] S. Kopetz,et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. , 2019 .
[85] Jeffrey S. Morris,et al. Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. , 2019, JCO precision oncology.
[86] M. Ychou,et al. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. , 2018, The oncologist.
[87] W. Scheithauer,et al. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. , 2017 .
[88] L. Rabeneck,et al. International Perspective on the Burden of Colorectal Cancer and Public Health Effects. , 2019, Gastroenterology.
[89] R. Danesi,et al. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial , 2019, JAMA oncology.
[90] E. Van Cutsem,et al. Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL - a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[91] P. Scheet,et al. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[92] Ying Cheng,et al. Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] Benjamin Werner,et al. Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. , 2018, Cancer discovery.
[94] A temporal shift of the evolutionary principle shaping intratumor heterogeneity in colorectal cancer , 2018, Nature Communications.
[95] F. Uno,et al. Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study , 2018, Oncology letters.
[96] Gary Middleton,et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. , 2018, Cancer discovery.
[97] G. Fontanini,et al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial , 2018, JAMA oncology.
[98] Roy S. Herbst,et al. The biology and management of non-small cell lung cancer , 2018, Nature.
[99] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] James X. Sun,et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 , 2018, Cancer.
[101] Ritika Kundra,et al. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. , 2018, Cancer cell.
[102] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[103] Benjamin J. Raphael,et al. The evolutionary history of 2,658 cancers , 2017, Nature.
[104] M. Oliveira,et al. KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. , 2018, Cancer research.
[105] N. Normanno,et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[106] James X. Sun,et al. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer , 2017, Journal of the National Cancer Institute.
[107] J. Desai,et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.
[108] A. Visekruna,et al. The Microbial Metabolite Butyrate Induces Expression of Th1-Associated Factors in CD4+ T Cells , 2017, Front. Immunol..
[109] A. Carrato,et al. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). , 2017, European journal of cancer.
[110] J. Pignon,et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[111] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[112] Frank McCormick,et al. RAS Proteins and Their Regulators in Human Disease , 2017, Cell.
[113] J. Meyerhardt,et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial , 2017, JAMA.
[114] L. Boni,et al. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group , 2017, BMC Cancer.
[115] S. Jaeger,et al. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer. , 2017, Cancer discovery.
[116] Weiwei Wang,et al. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. , 2017, Biochemical and biophysical research communications.
[117] T. Cenci,et al. A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation , 2017, British Journal of Cancer.
[118] James M Mullin,et al. The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for Non-Microbiologists. , 2017, Cancer research.
[119] C. Punt,et al. From tumour heterogeneity to advances in precision treatment of colorectal cancer , 2017, Nature Reviews Clinical Oncology.
[120] Ian D. Wilson,et al. Gut microbiota modulation of chemotherapy efficacy and toxicity , 2017, Nature Reviews Gastroenterology &Hepatology.
[121] Robyn L. Temple-Smolkin,et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] J. Guinney,et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.
[123] J. Guinney,et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.
[124] E. Frangou,et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. , 2016, The lancet. Gastroenterology & hepatology.
[125] F. Végran,et al. Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen. , 2016, Cancer research.
[126] F. Ciardiello,et al. Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence , 2016, ESMO Open.
[127] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[128] Jan Sundquist,et al. Patterns of metastasis in colon and rectal cancer , 2016, Scientific Reports.
[129] Sabine Tejpar,et al. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression , 2016, Clinical Cancer Research.
[130] N. Normanno,et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[131] V. Torri,et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[132] H. Clevers,et al. TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype , 2016, EMBO molecular medicine.
[133] A. Sartore-Bianchi,et al. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.
[134] Ian Tomlinson,et al. A panoply of errors: polymerase proofreading domain mutations in cancer , 2016, Nature Reviews Cancer.
[135] K. Hess,et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response , 2015, BMC Cancer.
[136] G. Fontanini,et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.
[137] A. Hinke,et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. , 2015, The Lancet. Oncology.
[138] C. Atreya,et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] P. Gibbs,et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[140] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[141] G. Meijer,et al. Serrated neoplasia—role in colorectal carcinogenesis and clinical implications , 2015, Nature Reviews Gastroenterology &Hepatology.
[142] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] T. Kuopio,et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer , 2015, British Journal of Cancer.
[144] Marc Peeters,et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. , 2015, The New England journal of medicine.
[145] C. Punt,et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group , 2015, The Lancet.
[146] E. Van Cutsem,et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. , 2015, The Lancet. Oncology.
[147] Sabine Tejpar,et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[148] M. Berger,et al. Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients , 2015, Clinical Cancer Research.
[149] G. Freeman,et al. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. , 2015, Cancer discovery.
[150] K. Kinzler,et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.
[151] M. Sade-Feldman,et al. Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. , 2014, Cancer research.
[152] A. Bardelli,et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. , 2014, Cancer discovery.
[153] C. Boni,et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. , 2014, The New England journal of medicine.
[154] G. Botti,et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. , 2014 .
[155] Hartmut Link,et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[156] Frank McCormick,et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.
[157] Marc Peeters,et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. , 2014, The Lancet. Oncology.
[158] Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[159] E. Van Cutsem,et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[160] F. Ciardiello,et al. Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells , 2013, Clinical Cancer Research.
[161] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[162] Reiko Nishihara,et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. , 2013, Journal of the National Cancer Institute.
[163] Susan Richman,et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial , 2013, The Lancet. Oncology.
[164] Stephen McLaughlin,et al. PIK3CA and PTEN Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer , 2013, Clinical Cancer Research.
[165] G. Brix,et al. Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model , 2013, Molecular Cancer Therapeutics.
[166] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[167] R. Greil,et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[168] E. Van Cutsem,et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[169] A. Russo,et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[170] M. Warmoes,et al. Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer , 2012, Clinical Cancer Research.
[171] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[172] Davide Corà,et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.
[173] C. Bokemeyer,et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[174] M. Vieth,et al. Up and downregulation of p16Ink4a expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer , 2011, Modern Pathology.
[175] Laetitia Huiart,et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. , 2011, JAMA.
[176] M. D'Angelica,et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[177] E. Chiorean. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011 .
[178] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[179] Shuji Ogino,et al. NRAS Mutations Are Rare in Colorectal Cancer , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[180] M. Pino,et al. The chromosomal instability pathway in colon cancer. , 2010, Gastroenterology.
[181] Ajay Goel,et al. Microsatellite instability in colorectal cancer. , 2010, Gastroenterology.
[182] J. Vincent,et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.
[183] Hiroyuki Yamamoto,et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.
[184] D. Tai,et al. Candidate Serological Biomarkers for Cancer Identified from the Secretomes of 23 Cancer Cell Lines and the Human Protein Atlas* , 2010, Molecular & Cellular Proteomics.
[185] F. Boisvert,et al. A Quantitative Proteomics Analysis of Subcellular Proteome Localization and Changes Induced by DNA Damage , 2009, Molecular & Cellular Proteomics.
[186] I. Nagtegaal,et al. BRAF mutation in metastatic colorectal cancer. , 2009, The New England journal of medicine.
[187] Sabine Tejpar,et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC , 2009, Nature Reviews Clinical Oncology.
[188] H. Ling. KRAS Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer , 2009 .
[189] W. Scheithauer,et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[190] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[191] G. Tortora,et al. EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.
[192] Guo-Min Li,et al. Mechanisms and functions of DNA mismatch repair , 2008, Cell Research.
[193] H. Hurwitz,et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients , 2008, Cancer Immunology, Immunotherapy.
[194] S. Rosenberg,et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. , 2007, The Journal of clinical investigation.
[195] P. Catalano,et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[196] Silvia Benvenuti,et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. , 2007, Cancer research.
[197] J. Meyerhardt,et al. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer , 2007, Gut.
[198] P. Laird,et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.
[199] J. Jiricny. The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.
[200] A. Lièvre,et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.
[201] M. Valerio,et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[202] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[203] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[204] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[205] Daniel J Sargent,et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[206] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[207] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[208] J. Herman,et al. CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[209] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[210] J. Hardcastle,et al. Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.
[211] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[212] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[213] N. Petrelli,et al. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. , 1987, NCI monographs : a publication of the National Cancer Institute.
[214] C. Heidelberger,et al. Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory Compounds , 1957, Nature.